

Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) – Expanded indication

- On June 19, 2019, the FDA approved Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.
 - Previously, Biktarvy was only approved in adult patients.
- The approval of Biktarvy's expanded indication was based on an open-label, single-arm study in virologically suppressed HIV-1 infected patients between the ages of 12 to less than 18 years weighing at least 35 kg (cohort 1; n = 50) and patients between the ages of 6 to less than 12 years weighing at least 25 kg (cohort 2; n = 50).
 - After switching to Biktarvy, 98% (49/50) of patients in cohort 1 remained suppressed (HIV-1 RNA < 50 copies/mL) at week 48. The mean change from baseline in CD4+ cell count at week 48 was -22 cells/mm³.
 - After switching to Biktarvy, 100% (50/50) of patients in cohort 2 remained suppressed (HIV-1 RNA < 50 copies/mL) at week 24. The mean change from baseline in CD4+ cell count at week 24 was -24 cells/mm³.
- Biktarvy carries a boxed warning for post-treatment acute exacerbation of hepatitis B.
- The recommended dosage of Biktarvy is one tablet taken orally once daily with or without food in adults and pediatric patients weighing at least 25 kg.
- Each Biktarvy tablet contains 50 mg of bictegravir, 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide.



optumrx.com

OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.